Summit Therapeutics Reports Third-Quarter Financial Results and Operational Progress
Summit Therapeutics reported financial results and operational progress for the third quarter and nine months ended September 30, 2026.
Story updates
09:36:20 PM UTC
SquawkNews
Summit reported Q3 and nine-month 2026 financial results, but the release provides no financial figures. AstraZeneca completed its $2.0B strategic equity investment on October 5, 2026; Summit cited an FDA PDUFA goal date of November 14 for its pending BLA.Material DetailsContext by AI AnalystThis i…
09:38:23 PM UTC
SquawkNews
Nov 04 (Reuters) - Summit Therapeutics Q3 operating expenses USD 214.6 million.